Three-year efficacy of complex insulin regimens in type 2 diabetes.

By Rury R. Holman, A. Farmer, M. Davies, J. Levy, J. Darbyshire, Joanne F Keenan, S. Paul. New England Journal of Medicine, 2009

648 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/93d1f0142ab95ed63a9fd387485091eef9dac907

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. R. Bergenstal
2. C. Apovian

Citations in the corpus

• Pharmacological management of obesity: an endocrine Society clinical practice guideline. (2015, background): “7 kg, detemir vs biphasic vs prandial, respectively) (93), and the weight advantage persisted during the 3-year trial (94).”
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “and/or symptomatic, a ‘basal’ insulin alone is typically added [74].”
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, background): “Insulin regimens based on basal or bolus insulin appear to be equally effective (21,64) and superior with respect to glycemic lowering compared to biphasic insulin-based regimens (63).”